Invex Therapeutics (ASX:IXC) Short-Term Debt : A$0.00 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Short-Term Debt?

Invex Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Invex Therapeutics Short-Term Debt Historical Data

The historical data trend for Invex Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Short-Term Debt Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Debt

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial						-	-	-	-	-

Invex Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Invex Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.